ALBO

Albireo Pharma Inc.

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$278.7M

Burn Rate (Qtr)

$30.7M

Company Profile

Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Odevixibat (A4250)

Progressive familial intrahepatic cholestasis (PFIC)

Regulatory Filings

H1 2020

Odevixibat

Alagille syndrome

Phase 3 To be Initiated

Q4 2020

Odevixibat (A4250)

Biliary atresia

Phase 3 To be Initiated

Q4 2020

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon